Varithena, a varicose vein treatment that dissolves veins as an alternative to surgical removal, should be available in the second quarter of 2014 after receiving FDA approval, its manufacturer announced.
Lovers of short skirts, rejoice: A new treatment for varicose veins has been approved in the U.S., its maker says.
British pharmaceutical firm BTG announced this week that its treatment, Varithena — previously known as Varisolve — has been given Food and Drug Administration approval.
Varithena uses an injectible foam to dissolve veins as an alternative to surgical removal, Reuters reported.
Speaking to Reuters on Tuesday, the company’s chief executive Louise Makin said the product would set a new standard for the treatment of both the symptoms and appearance of varicose veins.
“We look forward to the commercial U.S. launch in the second quarter of 2014, and to continuing to advance our plans to expand use into other geographies…
View original post 152 more words